OBIO Company Profile and Key Details

OBIO has shown sold momentum, gaining 16.63% over the past week and 77.29% over the past quarter, though year-to-date performance is up 16.63%. Short-term trend indicators are bearishly aligned (SMA20 8.91%, SMA50 9.58%, SMA200 45.27%). The stock’s 14-day RSI is 61.09 (firm momentum), while the ATR of 0.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.08% below its high and over 118.18% above its low. Average 10-day trading volume of 230.16 thousand shares is below the 3-month average of 293.57 thousand, indicating normal recent market interest.

Orchestra BioMed Holdings, Inc. has 53.96 million shares outstanding. The public float is 32.02 million shares, elevated short interest at 2.67% of float. This equals 506.57 thousand shares. The short ratio is 3.15 days. Institutional investors hold 41.71% of the float. Insiders own 16.13%. RTW INVESTMENTS, LP holds 3.64 million shares, PERCEPTIVE ADVISORS LLC has 1.50 million shares and Sherman Darren has 926.84 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Orchestra BioMed Holdings, Inc. generated EPS of -$1.82 over the past year. Five-year average earnings growth is -273.68%. Wall Street analysts project EPS growth of 10.6% annually over the next five years. The latest quarter delivered EPS of -$0.40. The next quarter is forecast at -$0.38. Next year's EPS is expected at -$12.75. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $10.00. The high target offers 316.67% upside. The low target suggests 108.33% downside. The mean target is $15.85. This offers 230.21% upside. Orchestra BioMed Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 5.26%. The prior quarter beat by -1.96%. Over the last six quarters, Apple has recorded several small beats. These include 9.76% in August 12, 2024.

Orchestra BioMed Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.11. This means the shares are trading above this model’s fair value.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) shares are up 16.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Orchestra BioMed Holdings, Inc. trading at a premium to the broader market with a P/E of -2.64. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $16.26, suggesting 238.75% upside. Our AI forecast model points to short-term weakness (-2.29% over two weeks), a medium-term fall (-25.0% over three months), and a longer-term gain (404.79% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Orchestra BioMed Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.29%, with price expected at $4.69 by January 23, 2026, within a range of $4.36 to $5.02 3-Month Outlook: Projected fall of -25.0%, reaching $3.60 by April 09, 2026, with a range of $3.44 to $3.76. 1-Year Outlook: Projected gain of 404.79%, with price at $24.23 by December 31, 2026, within a range of $11.45 to $37.17.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) closed at $4.80 USD, losing -$0.04 (-0.83%) from the previous close of $4.84. The stock is currently mid-range between its 52-week high and low $2.20 and $6.16. With a market capitalization of about $271.03 million, Orchestra BioMed Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.63). Key stats such as the average daily volume over the past year has been around 291.13 thousand shares, in line with its 52-week average. Headquartered in New Hope, PA, Orchestra BioMed Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Hochman, the company employs approximately 70 people and listed since August 04, 2020. Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.

Orchestra BioMed Holdings, Inc. trades at a P/E ratio of -2.64, slightly below the S&P 500 average, with a price-to-sales ratio of 92.06 and a price-to-book ratio of 624.7 reflecting a rich premium to book value. The P/FCF stands at -4.54, also above market averages. Compared to sector medians, Orchestra BioMed Holdings, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.